Rejuveron Life Sciences AG, a leader in biotechnology focused on aging therapies, has successfully secured USD $75 million in a Series B funding round. This financing was co-led by Catalio Capital Management and Apeiron Investment Group, with new participation from Mubadala Capital. The funds will bolster Rejuveron’s mission to extend healthspan and lifespan through its innovative medical portfolio.
The company has also announced the establishment of a new office in Abu Dhabi, UAE, aligning with its strategic expansion in the Middle East to advance regional healthcare innovation. This move includes forming collaborations with local institutions such as NYU Abu Dhabi to propel aging research.
Additionally, Rejuveron has expanded its scientific endeavors by acquiring a stake in Boost Neuroscience, a company spearheaded by Nobel Laureate Dr. Thomas Sudhof, focusing on brain synapse regeneration. This acquisition underscores Rejuveron’s commitment to pioneering in the field of aging and supporting groundbreaking scientific research.
The combination of strategic expansions, high-profile collaborations, and significant funding underscores Rejuveron’s position as a formidable force in the biotechnology industry, particularly in the realm of aging and longevity.